Combined modality therapy for stage III non-small-cell lung cancer.
With 40,000 to 50,000 patients diagnosed annually, stage III lung cancer represents approximately one third of all non-small-cell lung cancer cases. It is a heterogeneous disease stage encompassing stage IIIa, for which surgery in combination with chemotherapy and/or radiation therapy represents a treatment strategy for select patients, and stage IIIb, for which chemoradiation represents the prevailing standard of care. Overcoming unacceptably high rates of intrathoracic tumor failures remains a central obstacle. Current clinical trial efforts focus on targeted therapies, new chemotherapy regimens, dose-escalated radiation therapy, and improvements in radiation therapy treatment delivery.
Anderson
Cynthia S
CS
Department of Radiation Oncology, Emory University School of Medicine and Emory Winship Cancer Institute, Atlanta, GA, USA. cynthia@radonc.emory.org
Curran
Walter J
WJ
D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011300:Preoperative Care / Q000379:methods; D018714:Radiotherapy, Adjuvant / Q000379:methods